Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kinetic Energy00:23

Kinetic Energy

43.2K
Kinetic energy is the ability of an object in motion to do work or enact change. It can take on many forms. For instance, water flowing down a waterfall has kinetic energy. In biological systems, particles of light travel and are absorbed by plants to create chemical energy. Animals consume the chemical energy and give off molecules that carry their scent through the air. They also generate kinetic energy when they run away from predators. Entire systems also possess kinetic energy, like the...
43.2K
Enzyme Kinetics01:19

Enzyme Kinetics

103.9K
Enzymes speed up reactions by lowering the activation energy of the reactants. The speed at which the enzyme turns reactants into products is called the rate of reaction. Several factors impact the rate of reaction, including the number of available reactants. Enzyme kinetics is the study of how an enzyme changes the rate of a reaction.
Scientists typically study enzyme kinetics with a fixed amount of enzyme in the controlled environment of a test tube. When more reactant, or substrate, is...
103.9K
Kinetic Molecular Theory: Molecular Velocities, Temperature, and Kinetic Energy03:07

Kinetic Molecular Theory: Molecular Velocities, Temperature, and Kinetic Energy

29.7K
The kinetic molecular theory qualitatively explains the behaviors described by the various gas laws. The postulates of this theory may be applied in a more quantitative fashion to derive these individual laws.
29.7K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

812
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
812
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

712
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
712
Elimination Kinetics: First-Order and Zero-Order01:05

Elimination Kinetics: First-Order and Zero-Order

2.8K
Eliminating drugs from the body is a vital process that occurs through excretion or metabolism. Understanding the kinetics of drug elimination is crucial for drug development, dosage determination, and optimizing patient outcomes.
Drug clearance depends on the rate of drug elimination and its plasma concentration. Another important parameter is a drug's half-life, which is the time required for its concentration to decrease by half. In most cases, drug clearance follows first-order...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis-Related Safety Signals.

Pharmacoepidemiology and drug safety·2026
Same author

Resolving Signal Overlap in Fentanyl and Cocaine Detection Using Dual-pH Differential Pulse Voltammetry in Illicit Drug Samples.

ACS sensors·2026
Same author

Differences in higher-risk cannabis use outcomes across Canadian provinces and territories: A cross-sectional study.

Canadian journal of public health = Revue canadienne de sante publique·2026
Same author

Exploring Age and Sex Differences in the Use of Cannabis Vaping Products: Results From the Canadian Cannabis Survey 2020-2023.

Drug and alcohol review·2026
Same author

Higher risk cannabis use indicators among people living in Canada: a cross-sectional study examining the association with socio-demographic and socio-economic factors.

Substance abuse treatment, prevention, and policy·2026
Same author

Trends in hospitalizations for cannabinoid hyperemesis syndrome in Canada, 2016-17 to 2024-25.

Frontiers in public health·2026

Related Experiment Video

Updated: Jan 24, 2026

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

6.9K

Cannabis and Cannabinoids: Kinetics and Interactions.

Brian C Foster1, Hanan Abramovici2, Cory S Harris3

  • 1Faculty of Medicine, University of Ottawa, Ont, Canada.

The American Journal of Medicine
|June 2, 2019
PubMed
Summary

Cannabis products can cause drug interactions, especially concentrated forms. More research is needed on cannabis pharmacokinetics and patient monitoring is crucial when using cannabis with other medications.

Keywords:
CannabidiolCannabinoidsCannabisDrug interactionsMarijuanaTetrahydrocannabinol

More Related Videos

Employing Aeroponic Systems for the Clonal Propagation of Cannabis
03:41

Employing Aeroponic Systems for the Clonal Propagation of Cannabis

Published on: December 1, 2021

4.6K
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.9K

Related Experiment Videos

Last Updated: Jan 24, 2026

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

6.9K
Employing Aeroponic Systems for the Clonal Propagation of Cannabis
03:41

Employing Aeroponic Systems for the Clonal Propagation of Cannabis

Published on: December 1, 2021

4.6K
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.9K

Area of Science:

  • Pharmacology
  • Clinical Toxicology
  • Drug Interactions

Background:

  • Cannabis sativa and its derivatives are widely consumed, yet their clinical interaction potential is poorly understood, particularly for concentrated cannabinoid products.
  • The pharmacokinetics of most cannabis products are largely unknown, with significant variability where data exists.
  • Complexity of cannabis products and varied administration routes complicate clinical data extrapolation.

Purpose of the Study:

  • To review the current understanding of clinical interactions involving cannabis products.
  • To highlight the risks associated with concurrent use of cannabis and conventional therapeutics.
  • To emphasize the need for enhanced patient monitoring.

Main Methods:

  • Review of in vitro evidence regarding cannabinoid metabolism by cytochrome P450 enzymes.
  • Analysis of existing clinical reports on cannabis-related drug interactions and adverse events.
  • Assessment of pharmacokinetic variability and complexity of cannabis product formulations and delivery.

Main Results:

  • In vitro studies indicate major cannabinoids are substrates for key metabolic enzymes like cytochrome P450.
  • Clinical reports of cannabis-drug interactions and adverse events are increasing.
  • Consumers often perceive cannabis as safer than conventional drugs, despite growing evidence of risks.

Conclusions:

  • Patients using cannabis products concurrently with other medications face heightened risks of adverse events and therapeutic failure.
  • The variability in cannabis product composition and pharmacokinetics necessitates cautious use and enhanced clinical monitoring.
  • Further research into cannabis pharmacokinetics and drug-drug interactions is essential for patient safety.